Russia is a $9.2 billion pharmaceutical market where the rulebook on intellectual property is being rewritten in real time. [1]
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now Read Post »
Prosecute to Win: Why Your Drug Patent Portfolio Is Your Next Competitive Assertion Asset The moment a generic manufacturer files
Every year, brand-name pharmaceutical manufacturers watch billions of dollars in revenue disappear within weeks of a generic competitor hitting pharmacy
Every three years, a hospital’s pharmacy director sits across from a GPO account team and negotiates contracts that will govern
Patent Expiration Intelligence: The GPO Contract Weapon Hospitals Are Ignoring Read Post »
Every pharmaceutical patent filed with the FDA Orange Book names two things: who owns the invention, and who made it.
Most biotech executives say they allocate R&D capital rationally. Most are wrong. They favor programs with internal champions, compounds that
NPV and Profitability Index: How to Rank Your Biotech R&D Portfolio Read Post »
Between 2025 and 2030, the pharmaceutical industry will lose exclusivity on drugs generating more than $300 billion in annual revenue.
Read the Patent Cliff: How Recruiters Find Biopharma Talent Before Competitors Do Read Post »
You probably already know the number: 80 to 90 percent. That’s how much of a branded small-molecule drug’s revenue can
Before a pharmaceutical company files a single WARN notice, before a restructuring plan hits an SEC filing, before a CEO
Sign in or create a free account to read this DrugPatentWatch article
